Ulteriori informazioni
The Indian Government policies on development and growth of pharmaceutical industry have registered a sea change during the long period of 72 years from India's independence in 1947 to 2019. The establishment of the public sector undertakings (PSUs) at the beginning was to reduce dependence of active pharmaceutical ingredients (APIs) on the multinational companies (MNCs). The policies framed in late 1960s and early 1970s were built in difficult economic situation and experience of wars and the observations that multinational companies (MNCs) interested in trade in India were not ready to invest in APIs infrastructure unless compelled to. Indian industrial laws for manufacture and trade, abatement of monopoly, control of foreign exchange outflow as also protection of intellectual property rights on inventions were framed and modified to encourage manufacturing of bulk drugs and formulations locally with the primary aim of import-substitution; the indigenous industry was "protected" for a long period up to 1991 by administering "cost-plus" prices on selected bulk drugs and formulations made there from; their imports were regulated by levying heavy import duties.
Info autore
Prasanta Kumar Ghosh machte seinen M. Tech. in Chemieingenieurwesen und chemischer Technologie, gefolgt von einem PhD. Während seiner Tätigkeit in der indischen Zentralregierung war er an der Ausarbeitung und Umsetzung von Strategien für die Arzneimittel- und Pharmaindustrie sowie die Biotechnologiebranche beteiligt. Er ist Mitglied der Royal Society of Chemistry, Großbritannien, und der Institution of Engineers (Indien).
